In a population of 11 million inhabitants, the three shots have been administered to 4,258,396 people, of two vaccines developed in Cuba: Abdala, developed by the Center for Genetic Engineering and Biotechnology, and Soberana 02 and Soberana Plus, made by the Finlay Vaccines Institute.
The national director of Epidemiology at the Cuban Ministry of Public Health, Dr. Francisco Duran said that 16,195,960 doses have been administered since the beginning of the immunization strategy in the country in May.
To date, 60.6 percent of the population, that is, 6,784,652 people, got the first dose, and the second dose has been administered to 5,141,557 people, who account for 45.9 percent of the Cuban population.
As part of the vaccination program, these days the third dose of the vaccine is completed in the provincial capitals among risk groups such as pregnant women, post-partum breastfeeding women, transplanted patients and those with kidney diseases.
On September 3, 18-year-old adolescents who are in last year of senior high school as well as those in mid-level technical-professional schools got the first injection with the Abdala vaccine, a stage that should conclude on October 1.
Meanwhile, children also get their first dose these days, first to those between 12 and 18 years of age and shortly later those between 2 and 11 years of age.